Transgenomic's Sales Dip 5 Percent in Q3 | GenomeWeb

NEW YORK (GenomeWeb News) – Transgenomic reported after the close of the market Wednesday that its revenues in the third quarter had slipped 5 percent year over year.

Total revenues for the three months ended Sept. 30 dropped to $7.9 million from $8.3 million a year ago, as growth in the company's Clinical Laboratories segment was offset by a decline in the Pharmacogenomics Services and Diagnostic Tools segments, the Omaha, Neb.-based firm said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: adzuki bean genome, spontaneous mutation patterns in E. coli, and more.

An op-ed in the New York Times discusses banking of fecal samples to restore the gut microbiome.

Rules and regulations governing genetic modifications of human embryos vary from country to country, Nature News says, but such work may take place despite restrictions. is eyeing an expansion into genomic risk assessments, the Verge reports.